Director's Dealing • Jun 8, 2021
Director's Dealing
Open in ViewerOpens in native device viewer
Washington, D.C. 20549
OMB APPROVAL
OMB Number: 3235-0287 Estimated average burden hours per response... 0.5
Check this box if no longer subject to
Instruction 1(b).
Section 16. Form 4 or
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
| Mignone | 1. Name and Address of Reporting Person Roberto |
2. Issuer Name and Ticker or Trading Symbol Teva Pharmaceutical Industries Ltd. [TEVA] |
5. Relationship of Reporting Person(s) to Issuer (Check all applicable) ____ 10% Owner X |
|
|---|---|---|---|---|
| (Last) 5 Basel Street |
(First) (Middle) C/O Teva Pharmaceutical Industries Ltd. |
3. Date of Earliest Transaction (Month/Day/Year) 06/05/2021 |
Director _ Officer (give title below)_ Other (specify below) |
|
| (Street) Petach Tikva L3 4951033 (City) (State) (Zip) |
4. If Amendment, Date Original Filed (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person ____ Form filed by More than One Reporting Person |
| 1.Title of Security (Instr. 3) |
2. Transaction 2A. Deemed Date Execution Date, if (Month/Day/Year) any |
3. Transaction Code (Instr. 8) |
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) |
6. Ownership Form: |
7. Nature of Indirect Beneficial |
||||
|---|---|---|---|---|---|---|---|---|---|---|
| (Month/Day/Year) | Code | V | Amount | (A) or (D) |
Price | (Instr. 3 and 4) | Direct (D) or Indirect (I) (Instr. 4) |
Ownership (Instr. 4) |
||
| (1) Ordinary Shares |
06/05/2021 | M | 6,041 | A | (2) | 31,618 | D | |||
| (1) Ordinary Shares |
1,500,000 | I | see footnote (3) |
| 1. Title of Derivative Security (Instr. 3) |
2. Conversion or Exercise Price of Derivative Security |
3. Transaction Date (Month/Day/Year) |
3A. Deemed Execution Date, if any (Month/Day/Year) |
4. Transaction Code (Instr. 8) |
5. Number 6. Date Exercisable and of Expiration Date Derivative (Month/Day/Year) Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) |
7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
8. Price of Derivative Security (Instr. 5) |
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Code | V | (A) | (D) | Date Exercisable |
Expiration Date |
Title | Amount or Number of Shares |
||||||||
| Restricted Share Units |
(2) | 06/05/2021 | M | 6,041 | (4) | (4) | Ordinary Shares (1) |
6,041 | \$ 0 |
0 | D |
(1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
| /s/ Dov Bergwerk as attorney-in-fact for Roberto | |
|---|---|
| Mignone | 06/08/2021 |
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.